Compare ADMA Biologics Inc (ADMA) vs iShares International Treasury Bond ETF (IGOV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs iShares International Treasury Bond ETF — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while iShares International Treasury Bond ETF trades at $40.55. The key difference: ADMA Biologics Inc is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ADMA | IGOV | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | — |
52-Week High | $20.38 | $43.09 |
52-Week Low | $7.60 | $40.54 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
IGOV trades at $40.75, down 0.71% today, with a bearish technical signal driven by moving averages and key indicators like ADX signaling strong selling pressure. The stock lacks available fundamental data such as P/E and profit margins. Recent news highlights institutional interest, with DMC Group increasing its stake by 69.5% in Q1 2026, but also notes downside risks from global inflationary pressures affecting its bond holdings.
The outlook remains cautious due to technical bearishness and macroeconomic headwinds, though institutional accumulation may provide some support. Key risks include interest rate sensitivity and geopolitical tensions, warranting close monitoring of earnings and economic indicators for any turnaround signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →
